Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.

Author: BassettR, ConnickE, DemeterL, FischlM, FreimuthW, FriedlandG H, GriffithB, HirschM, HughesM, MorseG, NevinT, PollardR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Delavirdine + zidovudine + didanosine was safe and showed modest antiviral activity and CD4 cell count benefit compared with two-drug regimens in patients with HIV-1 infection. Gastrointestinal side effects and rash were reported.
Paper Details　
Original Abstract of the Article :
To evaluate the antiretroviral activity of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, we performed a phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00126334-199908010-00005

データ提供：米国国立医学図書館（NLM）

Delavirdine: A New Player in the HIV Treatment Arena

The fight against HIV continues to evolve, with researchers constantly seeking new and more effective treatment options. This study investigates the efficacy and safety of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, in combination with zidovudine and didanosine. The researchers compared this three-drug regimen to two-drug combinations, aiming to assess the potential benefits of adding delavirdine to existing therapies.

Delavirdine: A Promising Addition to HIV Treatment

The study, conducted on patients with HIV disease and CD4 cell counts between 100 and 500 cells/mm3, revealed that the three-drug regimen demonstrated modest, but not always significant, antiviral activity and CD4 cell count benefit compared to two-drug regimens. While gastrointestinal side effects were common, the majority of patients tolerated the treatment well. This study provides valuable data on the efficacy and safety of delavirdine in combination therapy, contributing to the ongoing efforts to develop more effective treatment strategies for HIV infection.

Navigating the Desert of HIV Treatment: A New Oasis of Hope

This study, like a caravan navigating a treacherous desert, explores the potential of delavirdine as a new therapeutic oasis for HIV patients. The findings, while encouraging, emphasize the need for continued research to refine treatment strategies and maximize the benefits of delavirdine in combination therapy.

Dr.Camel's Conclusion

The quest for effective HIV treatment is like searching for a hidden oasis in a vast desert. This study, like a seasoned desert guide, unveils the potential of delavirdine as a valuable addition to the therapeutic arsenal, offering hope for improved patient outcomes and a brighter future for those living with HIV.

Date :
  1. Date Completed 1999-08-09
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

10428106

DOI: Digital Object Identifier

10.1097/00126334-199908010-00005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.